CYP3A7抗体 [F19 P2 H2]

IHC-P analysis of human liver tissue using GTX79463 CYP3A7 antibody [F19 P2 H2].
Right : Primary antibody
Left : Negative control without primary antibody
Antigen retrieval : 10mM sodium citrate (pH 6.0) microwaved for 8-15 min
Dilution : 1:200

FACS analysis of HT29 cells using GTX79463 CYP3A7 antibody [F19 P2 H2] compared to an isotype control (blue).
Dilution : 1:40 for 60 min at room temperature
Fixation : 2% paraformaldehyde

IHC-P analysis of human kidney tissue using GTX79463 CYP3A7 antibody [F19 P2 H2].
Right : Primary antibody
Left : Negative control without primary antibody
Antigen retrieval : 10mM sodium citrate (pH 6.0) microwaved for 8-15 min
Dilution : 1:100

FACS analysis of Hela cells using GTX79463 CYP3A7 antibody [F19 P2 H2] compared to an isotype control (blue).
Dilution : 0.5 ug/test incubated for 30 min at 4ºC
Fixation : 2% paraformaldehyde

IHC-P analysis of human prostate carcinoma tissue using GTX79463 CYP3A7 antibody [F19 P2 H2].
Right : Primary antibody
Left : Negative control without primary antibody
Antigen retrieval : 10mM sodium citrate (pH 6.0) microwaved for 8-15 min
Dilution : 1:200

FACS analysis of HepG2 cells using GTX79463 CYP3A7 antibody [F19 P2 H2] compared to an isotype control (blue).
Dilution : 1:80 for 60 min at room temperature
Fixation : 2% paraformaldehyde

WB analysis of 25 ug of HepG2 (lane 1), Hela (lane 2) and HT29 (lane 3) cell lysates using GTX79463 CYP3A7 antibody [F19 P2 H2].
Dilution : 1:1000